People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

20 Sep 2019
Change (% chg)

$0.32 (+0.99%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Conner, Edward 

Mr. Edward R. Conner has been appointed Senior Vice President and Chief Medical Officer of the Company, effective July 15, 2019. Ed joins Audentes from Sangamo Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company's pipeline of genomic therapies. Prior to Sangamo, Ed served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc., where he led the global clinical development efforts for two of the company's rare disease product candidates. Prior to Ultragenyx, Ed served as Senior Medical Director at BioMarin Pharmaceutical Inc., where he led clinical development and regulatory interactions for its global Phase 3 program in Pompe disease, and earlier in his career Ed served as Medical Director at Genentech, Inc. where he was the clinical science team leader of two product candidates, including XOLAIR®. Ed completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco .

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --